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Abstract
Currently, over 15% of new HIV infections occur in children. Breastfeeding is a major contributor to HIV infections in infants.
This represents a major paradox in the field because in vitro, breast milk has been shown to have a strong inhibitory effect
on HIV infectivity. However, this inhibitory effect has never been demonstrated in vivo. Here, we address this important
paradox using the first humanized mouse model of oral HIV transmission. We established that reconstitution of the oral
cavity and upper gastrointestinal (GI) tract of humanized bone marrow/liver/thymus (BLT) mice with human leukocytes,
including the human cell types important for mucosal HIV transmission (i.e. dendritic cells, macrophages and CD4
+ T cells),
renders them susceptible to oral transmission of cell-free and cell-associated HIV. Oral transmission of HIV resulted in
systemic infection of lymphoid and non-lymphoid tissues that is characterized by the presence of HIV RNA in plasma and a
gradual decline of CD4
+ T cells in peripheral blood. Consistent with infection of the oral cavity, we observed virus shedding
into saliva. We then evaluated the role of human breast milk on oral HIV transmission. Our in vivo results demonstrate that
breast milk has a strong inhibitory effect on oral transmission of both cell-free and cell-associated HIV. Finally, we evaluated
the effect of antiretrovirals on oral transmission of HIV. Our results show that systemic antiretrovirals administered prior to
exposure can efficiently prevent oral HIV transmission in BLT mice.
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Introduction
Pediatric HIV infection is associated with an accelerated course
of disease and high mortality rate. In the absence of antiretroviral
therapy, only 65% of HIV-infected children survive until their first
birthday and less than half will reach two years of age [1]. Most
children acquire HIV from their mother in utero, intrapartum or
orally during breastfeeding [2]. In developed countries the
incidence of mother-to-child transmission of HIV is extremely
low; HIV-infected women receive antiretroviral therapy during
pregnancy and delivery and abstain from breastfeeding. Further-
more, their children receive antiretroviral prophylaxis at birth and
for several weeks thereafter. The majority of HIV-infected
children live in sub-Saharan Africa where HIV-positive women
have limited access to antiretroviral drugs and the health benefits
of breastfeeding outweigh the risk of HIV transmission [3].
Despite the presence of innate factors in human breast milk that
display strong HIV inhibitory activity in vitro [4–12], up to 44% of
HIV infections in children can be attributed to breastfeeding. The
risk of acquiring HIV after a single day of breastfeeding is
extremely low (0.00028 per day of breastfeeding) [13], however,
after ingesting liters of breast milk over a span of several months to
years (,250 liters per year), 5–20% of infants born to HIV-
infected women will eventually become infected with HIV in
the absence of any preventative measures [14]. Exclusive
breastfeeding (not allowing any water, juice or solid foods) has
been associated with a drastic decrease in the HIV transmission
rate through breastfeeding, indicating that breast milk acts as a
vehicle of protection [14]. However, elevated levels of HIV
particles (cell-free virus) and HIV-infected cells (cell-associated
virus) in breast milk of HIV-positive women are associated with an
increased risk for HIV transmission during breastfeeding [15–17].
Although it has been reported that a 10-fold increase in cell-free or
cell-associated HIV in breast milk is associated with a 3-fold
increase in transmission [15], it is still unclear whether cell-free
and/or cell-associated virus are transmitted during breastfeeding.
Furthermore, it is not known if the frequency of cell-free and cell-
associated HIV transmission varies at different stages of lactation
(i.e. colostrum, early breast milk and mature breast milk).
Therefore, successful interventions may need to prevent transmis-
sion of both cell-free and cell-associated HIV during breastfeeding
by reducing the viral load and number of infected cells in breast
milk and/or by directly inhibiting infection of the infant oral and
GI mucosa.
The development of effective strategies to prevent HIV
acquisition during breastfeeding would be significantly enhanced
by a small animal model of oral HIV infection that could be
utilized to study the relative contribution of cell-free and cell-
associated virus in transmission, the mechanism for oral transmis-
sion of cell-free and cell-associated HIV and the innate HIV
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models are needed to test the efficacy of novel approaches to
prevent transmission of cell-free and cell-associated HIV in breast
milk. Thus, we developed an oral HIV transmission model based
on BLT humanized mice [18]. We then used this model to
demonstrate 1) efficient cell-free and cell-associated oral HIV
transmission, 2) transmission can occur in the oral cavity or the
upper GI tract, 3) transmission can be prevented with antivirals
and 4) that human breast milk dramatically reduces oral HIV
transmission.
Results
BLT humanized mice are created by transplanting autologous
fetal liver-derived human CD34
+ hematopoietic progenitor cells
into mice previously implanted with a piece of human fetal liver
sandwiched between two small pieces of human fetal thymus.
Humanized BLT mice show robust reconstitution with virtually all
human hematopoietic cell types that are present in primary,
secondary and effector immune organs. The immune cells present
in BLT humanized mice have been shown to be able to mount
both humoral and cellular immune responses to model antigens
and viruses. Our laboratory has further established that the
systemic reconstitution with human hematopoietic cells renders
BLT humanized mice susceptible to parenteral, rectal and vaginal
HIV infection [19–24]. More recently, we also demonstrated that
BLT mice can be utilized to assess the efficacy of pre- and post-
exposure antiretroviral prophylactic strategies to prevent mucosal
and parenteral HIV infection [19–22].
Reconstitution of the oral cavity of BLT mice with human
hematopoietic cells
Highlighting the importance of the oral cavity as the first site of
exposure for HIV that is transmitted during breastfeeding, our
initial aim for this study was to examine if the oral mucosa of BLT
mice is repopulated with human hematopoietic cells. For this
purpose, we used immunohistochemistry (IHC) analysis. Specifi-
cally, we determined whether the oral mucosa of BLT mice is
reconstituted with human hematopoietic (CD45
+) cells that
include the types of cells known to play an essential role in
mucosal HIV transmission: human dendritic cells (CD11c
+),
macrophages (CD68
+), B cells (CD20
+) and T cells (CD3
+).
In the oral mucosa of BLT mice, human macrophages were
detected in the epithelial layer, near the basement membrane, and
in the lamina propria whereas human dendritic cells were
predominantly present in the lamina propria. Human CD4
+ and
CD8
+ T cells were also present in the epithelial layer, appearing as
a band at the basement membrane, and in the underlying lamina
propria. In contrast, IHC analysis did not detect the presence of
human B cells in either the epithelium or lamina propria in the
oral mucosa of BLT mice (Figure 1). While comparable studies in
humans are limited, macrophages, dendritic cells and T cells have
also been identified in the oral mucosa of infants [25]. In addition,
although the presence of B cells in the oral mucosa of infants has
not been investigated, our data demonstrating a lack of B cells in
the oral mucosa of BLT mice is consistent with what has been
described in human adults [26]. All together, these results indicate
that the oral mucosa of BLT mice, like infants, possesses human
macrophages, dendritic cells and T cells, the human cell types
important for HIV transmission.
Next, we used IHC to determine if human hematopoietic cells
are present in the salivary glands and lymphoid tissues proximal to
the oral mucosa of BLT humanized mice, as these tissues may
serve as early sites for viral dissemination. The salivary glands are
directly connected to the oral mucosa by excretory ducts that
secrete saliva into the oral cavity. In infected humans, HIV-
infected cells have been identified in the salivary glands and HIV
RNA has been detected in saliva [27–29]. IHC analysis revealed
that the salivary glands of BLT mice are reconstituted with human
target cells for HIV infection (macrophages, dendritic cells and
CD4
+ T cells) as wells as human CD8
+ T cells and B cells
(Figure 1). The cervical lymph nodes (CLN), which drain the oral
mucosa, and the nasal-associated lymphoid tissue (NALT) of BLT
mice were also repopulated with human macrophages, dendritic
cells, T cells and B cells (Figure 1). Collectively, these data
demonstrate that the oral cavity of BLT mice is reconstituted with
human hematopoietic cells including all of the human cell types
important for HIV transmission and dissemination (i.e. dendritic
cells, macrophages and CD4
+ T cells).
Identification of HIV target cells in the upper GI tract of
BLT mice
Although the oral mucosa is the first surface exposed to HIV
that is transmitted through breastfeeding, it is not clear if
transmission occurs in the oral cavity or in the upper GI tract of
infants. HIV is typically inactivated in acidic environments like the
stomach but the pH of the infant stomach is considerably higher
than that of adults [30] which may allow transmission to occur in
the upper GI tract. Therefore, we used IHC to determine if the
human cell types important for HIV transmission are present in
the esophagus, stomach and upper small intestine of BLT mice.
IHC analysis demonstrated the presence of CD45
+ human cells in
the esophagus, stomach and duodenum of BLT mice. Specifically,
human dendritic cells, macrophages and CD4
+ T cells were all
present in these tissues (Figure 2). We also identified a dense
population of human hematopoietic cells at the gastroesophageal
(GE) junction, where the esophagus joins the stomach (Figure S1).
In regard to the relative distribution of HIV target cells in the
upper GI tract, in the esophagus of BLT mice, human
macrophages, dendritic cells and CD4
+ T cells were located in
the basal layer of the epithelium and in the lamina propria
(Figure 2). Human dendritic cells, macrophages and CD4
+ T cells
Author Summary
Infected children acquire HIV from their mother in utero,
intrapartum or by ingesting their mother’s breast milk
which can contain both HIV particles (cell-free) and HIV-
infected cells (cell-associated). Although breastfeeding is
attributed to a significant number of HIV infections in
children, most breastfed infants remain uninfected despite
prolonged and repeated exposure to HIV. This limited
transmission has led to two apparently contradictory roles
for milk in HIV infection: vector of transmission or vehicle
of protection? Milk has a strong inhibitory effect on HIV
infection in vitro. However, this has never been demon-
strated in an in vivo system. In the present study, we
address this paradox in a bone marrow/liver/thymus (or
BLT) humanized mouse model of oral transmission of cell-
free and cell-associated HIV. We demonstrate that human
breast milk has potent HIV inhibitory activity that can
prevent oral transmission of cell-free and cell-associated
HIV in vivo. Our results provide key insight into oral HIV
transmission and the protective role of milk. However,
since transmission can and does occur in some instances
after continued exposure to HIV in milk, we demonstrate
that oral HIV transmission can be efficiently prevented in
BLT humanized mice by the systemic administration of
antiretrovirals.
Human Breast Milk Inhibits Oral HIV-1 Transmission
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stomach as well as the lamina propria of the duodenum (Figure 2).
These findings are consistent with previous reports which
demonstrated reconstitution of the gastrointestinal tract of BLT
mice with human target cells for HIV infection [23,31]. Although
the presence and distribution of these immune cell types in the
esophagus, stomach and upper intestine of human infants has not
been systematically explored, macrophages, dendritic cells and
CD4
+ T cells have been identified in the upper GI tract of healthy
adults [29,32–36]. All together, these results demonstrate robust
reconstitution of the upper GI tract of BLT mice with human cells
highlighting the potential for transmission to occur at these
important mucosal sites.
Oral transmission of HIV in BLT humanized mice
Once we established the presence of human target cells for HIV
infection in the oral cavity and upper GI tract of BLT mice, we
proceeded to determine if BLT mice are susceptible to oral HIV
infection. For this purpose, we exposed BLT mice to a single dose
of cell-free HIV-1JR-CSF, a CCR5-tropic isolate, administered
directly into the oral cavity. We then monitored infection in
peripheral blood by measuring viral load levels essentially as we
have previously described [22]. In addition, as a measure of the
pathogenic effects of HIV infection, we also monitored human
CD4
+ T cell depletion in peripheral blood. Consistent with the
presence of HIV target cells in the oral mucosa and upper GI tract
of BLT mice, reproducible oral HIV transmission was observed.
Specifically, viral RNA was readily detected in the plasma of all
BLT mice exposed orally to HIV-1JR-CSF (Figure 3A). The
presence of viral RNA in the plasma of infected mice preceded a
significant decrease in the percentage of CD4
+ T cells in the
peripheral blood that became evident at three weeks post-exposure
(Figure 3A).
Once infection was confirmed in the plasma of these mice, we
also determined the presence of viral RNA in saliva. Our results
demonstrate the presence of HIV RNA in the saliva of 4/5
infected BLT mice examined. Consistent with what is observed in
humans, the viral load in the saliva of each BLT mouse was lower
than the viral load in plasma (Figure 3B) [27,28]. The presence of
viral RNA in the saliva of BLT mice is consistent with the
productive infection of human hematopoietic cells within the oral
mucosa and/or salivary glands of BLT mice. Taken together,
these findings demonstrate BLT humanized mice are susceptible
to oral HIV transmission that results in systemic infection, as
demonstrated by the presence of HIV RNA in plasma and saliva.
Transmission of HIV via the upper GI tract in BLT mice
Following ingestion of breast milk from HIV-infected mothers,
HIV transmission to neonates may occur in the oral cavity and/or
upper GI tract. In BLT humanized mice, this could also be the
case given the robust reconstitution of the oral cavity and upper GI
tract with human dendritic cells, macrophages and CD4
+ T cells.
In order to determine if HIV transmission can occur distal to the
esophagus, we introduced HIV-1JR-CSF directly into the stomach
of BLT mice by oral gavage. After exposure by gavage, viral RNA
could be readily detected in the plasma of all BLT mice two weeks
post-exposure (Figure 4). This finding indicates that the mucosal
surfaces of BLT mice distal to the oral cavity can be directly
infected with HIV to effect transmission. These results serve as
evidence for this mode of HIV transmission.
Figure 1. Reconstitution of the oral cavity of humanized BLT mice with human hematopoietic cells. The oral mucosa, salivary glands,
CLN and NALT were harvested from BLT mice and stained with the appropriate antibodies to verify the presence of human leukocytes (CD45
+)
including dendritic cells (CD11c
+), macrophages (CD68
+), B cells (CD20
+), T cells (CD3
+), CD4
+ T cells (CD4
+) and CD8
+ T cells (CD8
+). Positive cells
appear brown. Scale bars=100 mm.
doi:10.1371/journal.ppat.1002732.g001
Human Breast Milk Inhibits Oral HIV-1 Transmission
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exposure
In humans, once HIV establishes an infection, lymphoid organs
become the primary site of viral replication which subsequently
allows HIV to disseminate to distal tissues resulting in a systemic
infection [37]. In order to evaluate the systemic nature of the
infection that occurs after oral exposure, we harvested tissues from
infected BLT mice 2–8 weeks post-exposure. IHC analysis
demonstrated the presence of productively infected (HIV p24
Gag
+) cells in the mucosal tissues of the oral cavity and upper GI
tract of BLT mice. We observed infected cells in the oral mucosa
and salivary glands of BLT mice as wells as in proximal lymphoid
tissues (CLN and NALT) (Figure 5A). HIV-infected cells were also
identified in the esophagus, stomach and duodenum of BLT mice
following oral transmission (Figure 5A). Substantiating the role of
lymphoid tissues as the principal site for productive virus infection,
HIV-infected cells were detected in the spleen and lymph nodes of
infected BLT mice (Figure 5B). Furthermore, we observed viral
dissemination into non-lymphoid tissues including the lung and
liver (Figure 5B). These results demonstrate systemic infection of
BLT mice following oral HIV transmission and highlight some of
the remarkable similarities in HIV infection between humans and
BLT mice.
Susceptibility of BLT mice to HIV-1 transmitted/founder
viruses
During mucosal transmission, HIV encounters several physical
and immunologic barriers that allow only one to a few variants
from a diverse donor pool to cross the mucosa and establish
systemic infection (reviewed in [38,39]). A better understanding of
the molecular and biological determinants that bestow a selective
advantage for mucosal transmission of these transmitted/founder
(T/F) viruses will aid the development of novel vaccines and other
prevention strategies. Hence, our next objective was to determine
if CCR5-tropic T/F viruses can establish a systemic infection in
BLT mice following an oral exposure.
We exposed groups of BLT mice orally to one of three different
T/F viruses: HIV-1RHPA, HIV-1CH040 or HIV-1CH077 [40–42].
All of these T/F viruses replicate efficiently in activated primary
human CD4
+ T cells in vitro [41]. As a control, BLT mice were also
exposed to HIV-1JR-CSF. In order to appreciate any subtle
difference in transmission efficiency between HIV-1JR-CSF and
the three T/F viruses, BLT mice were orally administered a single
lower dose of HIV (6610
5 TCIU). Even at this lower dose, at two
weeks post-exposure, viral RNA was detected in the plasma of
75% of BLT mice exposed orally to HIV-1JR-CSF. The T/F virus
HIV-1CH040 was also readily transmitted following oral exposure
(100%). Only 66% and 33% of BLT mice orally exposed to HIV-
1RHPA and HIV-1CH077 respectively became infected (Table 1).
These results indicate that BLT mice are susceptible to oral
transmission of T/F viruses and that T/F viruses may not be
equally capable of oral transmission. Furthermore, these findings
demonstrate that BLT mice can be used to evaluate the
transmission efficiency of T/F viruses.
Oral transmission of cell-associated HIV in BLT mice
Cell-free and cell-associated HIV can be detected in the breast
milk of HIV-infected women and it is currently unclear if either or
both are responsible for the transmission event resulting in
Figure 2. The upper GI tract of humanized BLT mice is repopulated with HIV target cells. The esophagus, stomach and duodenum were
harvested from BLT mice for IHC analysis to determine if these potential sites for HIV transmission following an oral exposure possess HIV target cells.
The tissues harvested were stained with the appropriate antibodies to verify the presence of human leukocytes (CD45
+) including dendritic cells
(CD11c
+), macrophages (CD68
+) and T cells (CD3
+), specifically, CD4
+ T cells (CD4
+). Positive cells appear brown. Scale bars=100 mm.
doi:10.1371/journal.ppat.1002732.g002
Human Breast Milk Inhibits Oral HIV-1 Transmission
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transmission of cell-free HIV, we established the oral transmission
of cell-associated HIV. For this purpose, we first generated stocks
of allogeneic human PBMCs infected with HIV-1JR-CSF in vitro.
The efficiency of infection and the numbers of productively
infected cells in the individual stocks were determined by
intracellular staining for HIV p24 Gag and subsequent flow
cytometric analysis. BLT mice were then exposed orally to a single
dose of HIV-infected cells (3.75610
5 HIV Gag p24
+ cells) and
monitored for infection by determining the presence of viral RNA
in peripheral blood plasma. We observed 100% transmission by
two weeks post-exposure when BLT mice were exposed orally to a
single inoculum of HIV-infected cells (Figure 6A). These results
demonstrate efficient oral transmission of cell-associated HIV.
Similartooralexposuretocell-freeHIV,followingtheappearance
of viral RNA in plasma, oral transmission of cell-associated HIV was
characterized by a significant decrease in the percentage of CD4
+ T
cells in peripheral blood (Figure 6A). Also similar to what we
observedaftercell-free HIV infection,wereadilydetected HIV RNA
in the saliva of all BLT mice evaluated following oral transmission of
cell-associated HIV (Figure 6B).
Since transmission of HIV in humans may occur in the upper
GI tract, we also determined whether cell-associated HIV could
infect BLT mice if they were exposed by gavage, bypassing the
oral cavity. When HIV-infected cells were directly introduced into
the stomach of BLT mice by gavage, we observed 100%
transmission (Figure 6C). These results indicate that the mucosal
surfaces distal to the esophagus are susceptible to infection with
cell-associated HIV and that transmission of cell-associated HIV
can occur in the oral cavity and/or upper GI tract.
Effect of human breast milk on oral HIV transmission
Since the vast majority oral HIV transmission events occur in
the context of human breast milk, we next investigated the impact
of human breast milk on oral transmission of HIV in BLT mice.
We began by evaluating the ability of whole breast milk obtained
from five HIV-negative lactating women to inhibit in vitro HIV-
1JR-CSF infection. In all cases, consistent with previous reports,
whole breast milk had a complete inhibitory effect on virus
infectivity (Figure 7A). We also observed that the ability of each
breast milk sample to inhibit HIV infection in vitro was
concentration dependent (Figure 7B).
We then determined whether human breast milk can inhibit
oral HIV transmission. For this purpose, we exposed groups of
BLT mice orally to a single dose of cell-free HIV-1JR-CSF in the
presence or absence of whole human breast milk. Following oral
exposure, HIV transmission was evaluated as indicated above.
Whereas in the absence of breast milk HIV RNA was detected in
the peripheral blood plasma of all control mice exposed orally to
HIV-1JR-CSF, no transmission events occurred when the virus was
orally administered in the presence of breast milk. Specifically, we
did not detect HIV RNA in the peripheral blood plasma of any
Figure 3. Oral transmission of cell-free HIV in humanized BLT
mice. (A) BLT mice (n=10) were exposed orally to the CCR5-tropic HIV-
1 isolate JR-CSF. Infection was monitored weekly by measuring the
plasma viral load and percentage of human CD4
+ T cells in peripheral
blood. A two-tailed Mann-Whitney U test was used to compare the
percentages of CD4
+ T cells in peripheral blood pre-exposure (week 0)
and post-exposure (p values,0.05 are indicated with an asterisk). (B)
Saliva and peripheral blood (PB) were collected from five BLT mice 5–8
weeks following oral HIV exposure. Saliva was collected on the same
day as peripheral blood or one week later. The corresponding saliva and
peripheral blood viral loads for each mouse are shown with the same
shape. The limit of detection for the assay is illustrated with a dashed
line.
doi:10.1371/journal.ppat.1002732.g003
Figure 4. Susceptibility of BLT mice to HIV infection after
administration via gavage. To determine if the upper GI tract of BLT
mice is susceptible to HIV transmission, we evaluated HIV acquisition
after a single direct administration of virus to the upper GI tract via
gavage. Infection was monitored in peripheral blood by determining
the levels of viral load in BLT mice (n=4) receiving cell-free HIV-1JR-CSF
directly into the stomach by gavage. The viral load (RNA copies/ml) for
each mouse is indicated and the limit of detection for the assay is
illustrated with a dashed line.
doi:10.1371/journal.ppat.1002732.g004
Human Breast Milk Inhibits Oral HIV-1 Transmission
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breast milk at any time point post-exposure (Figure 7C). PCR
analysis for the presence of viral DNA in cells isolated from tissues
harvested from BLT mice exposed orally to HIV in human breast
milk failed to detect the presence of HIV DNA in any tissue
analyzed. In contrast, HIV DNA was readily detected in cells
isolated from the peripheral blood and tissues of all BLT mice
exposed orally to virus in the absence of breast milk (Table 2). In
addition, to confirm that the BLT mice exposed orally to HIV in
breast milk were indeed susceptible to HIV infection, three weeks
following the original oral exposure to cell-free HIV in breast milk
of donor 1, these same BLT mice (mice 11–13) were re-exposed
orally to the same virus in the absence of milk. Under these
conditions the virus was readily transmitted (Table 2). Together,
the results of these experiments highlight the potent HIV
inhibitory activity of normal human breast milk and demonstrate
that the in vitro HIV inhibitory activity of human breast milk is also
capable of efficiently preventing oral transmission of cell-free HIV.
Once we established that whole human breast milk can inhibit
oral transmission of cell-free HIV in BLT mice, we proceeded to
determine the potential inhibitory effect of human breast milk on
oral transmission of cell-associated HIV given that both cell-free
and cell-associated HIV can be detected in the breast milk of HIV-
infected women [15,43–45]. We evaluated the impact of human
breast milk on oral transmission of cell-associated HIV using
breast milk that inhibited oral transmission of cell-free HIV-1JR-CSF.
In stark contrast to the robust transmission of cell-associated HIV
afteroralexposureintheabsence ofbreastmilk,cell-associatedHIV
was not capable of establishing a productive infection when oral
exposures occurred in the presence of breast milk. Specifically, we
did not detect HIV RNA in the plasma of BLT mice that were
exposed orally to HIV-infected cells re-suspended in the breast milk
of donors 1 or 2 at any time point post-exposure (Figure 7D).
Furthermore, the lack of HIV transmission was confirmed at
necropsy when no HIV DNA was detected in the peripheral blood
or tissues of any BLT mouse exposed to cell-associated HIV in the
presence of human breast milk (Table 3). Collectively, these data
demonstrate that BLT mice are susceptible to oral transmission of
cell-associated HIV and that human breast milk possesses innate
factors that can potently inhibit oral transmission of both cell-free
and cell-associated HIV.
Prevention of oral HIV transmission by antiretroviral pre-
exposure prophylaxis
Previously our laboratory demonstrated that BLT mice
administered systemic pre-exposure prophylaxis (PrEP) of emtri-
citabine (FTC)/tenofovir disoproxil fumarate (TDF) were effi-
ciently protected from HIV-1 infection following intravenous,
rectal and vaginal challenges [19,20]. To assess whether systemic
FTC/TDF PrEP can also prevent oral transmission of HIV-1 in
BLT mice, we administered systemic FTC/TDF to BLT mice
once daily for 7 days and exposed mice orally to cell-free HIV-1JR-
CSF 3 hours after the third administration of antiretrovirals as
previously described [19,20]. Subsequently, HIV transmission was
monitored in peripheral blood by measuring the plasma viral load.
In addition, at necropsy we utilized real-time PCR to evaluate
whether HIV DNA was present in the peripheral blood or any
tissues harvested from BLT mice. No viral RNA was detected in
the peripheral blood plasma of any BLT mouse receiving the 7-
Figure 5. Infection of the oral cavity and upper GI tract
following oral HIV transmission. (A) Tissues were harvested from
the oral cavity and upper GI tract of infected BLT mice following oral
HIV exposure and stained with an antibody directed against HIV p24
Gag. (B) HIV p24 Gag staining also identified infected cells in peripheral
lymphoid, mucosal and non-mucosal tissues isolated from infected BLT
mice outside of the oral cavity and upper GI tract. HIV-infected cells
appear brown. Scale bars=100 mm.
doi:10.1371/journal.ppat.1002732.g005
Human Breast Milk Inhibits Oral HIV-1 Transmission
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We also did not detect the presence of HIV DNA in their
peripheral blood or in any of their tissues at necropsy confirming
lack of infection (Table 4). These results demonstrate that oral
transmission of HIV in BLT mice can be efficiently prevented by
the administration of systemic FTC/TDF and serve as a proof of
concept for future studies aimed at evaluating the efficacy of novel
HAART strategies.
Discussion
Avoidance of breastfeeding by HIV seropositive mothers in
resource limited settings where prophylaxis is not available reduces
the risk of HIV transmission but does not increase the overall
survival of their children; breastfeeding protects these children
from infections that result in diarrhea, pneumonia and sepsis [14].
In this study, we first established that human hematopoietic cells
generated in situ are capable of repopulating the oral cavity and
upper GI tract of humanized BLT mice. Specifically, these
important mucosal tissues of BLT mice are repopulated with the
types of human cells that have been identified to be important for
mucosal HIV transmission (i.e. dendritic cells, macrophages and
CD4
+ T cells). Our results demonstrate that the presence of these
human cells renders BLT mice susceptible to oral transmission of
cell-free and cell-associated HIV. Oral transmission of HIV results
in systemic infection of lymphoid and non-lymphoid tissues that is
characterized by a gradual decline of CD4
+ T cells in peripheral
blood. In addition, infection of the oral cavity results in virus
shedding into saliva, recapitulating the human condition [27,28].
Our data also offers the first in vivo demonstration that human
breast milk can inhibit oral transmission of cell-free and cell-
associated HIV. Furthermore, oral transmission of HIV can be
prevented with systemic FTC/TDF PrEP.
Previous studies utilizing NOD/SCID and NOD/SCID/b2m
2/2
mice reconstituted with human peripheral blood leukocytes (hu-PBL
mice) failed to demonstrate oral transmission of cell-free HIV
following an oral exposure to CXCR4 and CCR5 tropic strains,
including HIV-1JR-CSF [46]. Therefore, our work represents a
significant advance since we demonstrated, for the first time, highly
reproducible oral transmission of multiple HIV strains in BLT mice.
Specifically, in this study we demonstrate oral transmission of the well
characterized CCR5-tropic HIV-1 isolate JR-CSF and of several T/
F viruses. Our data revealed that the efficiency of oral transmission
variedamongT/Fviruses,suggestingthatintrinsicpropertiesofthese
viruses may contribute to their transmission in vivo. Recent studies of
mother-infant transmission pairs indicate that the replicative fitness as
well as the length of the variable loop and number of n-linked
glycosylation sites in the envelope protein may influence which
maternal variant(s) are preferentially transmitted [47–49]. Our results
indicate that BLT mice could be used to study the molecular and
biological properties of HIV strains that provide a selective advantage
for oral transmission during breastfeeding. A comparison of viruses
transmitted at early, mid and late stages of lactation would indicate if
the composition of breast milk, which changes during lactation,
influences which viruses are preferentially transmitted.
During breastfeeding, HIV is transmitted from mother-to-child
in the context of human breast milk. In the absence of
antiretroviral therapy, the breast milk of most HIV-infected
women possesses cell-free and/or cell-associated HIV [15–17].
Although elevated levels of both cell-free and cell-associated HIV
in the breast milk of HIV-infected mothers have been associated
with an increased risk for HIV transmission during breastfeeding
[15–17], it is currently not known if both cell-free and cell-
associated HIV are transmitted to infants. Studies illustrating that
HAART administered to HIV-infected mothers during pregnancy
or post-partum significantly decreases the amount of cell-free but
not cell-associated HIV in breast milk [50,51], combined with
reports demonstrating that maternal HAART significantly de-
creases but does not eliminate HIV transmission during breast-
feeding, suggest that both cell-free and cell-associated HIV may be
transmitted [52,53]. As the importance of cell-associated HIV in
breast milk transmission becomes increasingly more appreciated,
antiretroviral drugs and preventative strategies may be needed that
reduce the burden of HIV-infected cells in the breast milk of HIV-
infected women and/or directly inhibit transmission of cell-
associated HIV in infants during breastfeeding. Our data
demonstrating oral transmission of both cell-free and cell-
associated HIV is of high relevance since it will make possible
the future evaluation of novel prophylactic strategies aimed at
preventing oral transmission of both cell-free and cell-associated
HIV. However, even though infected cells were used for the
exposures, we cannot rule out the possibility that actual
transmission across the mucosal surface could occur with cell-free
virions released from infected cells.
Paradoxically, although breastfeeding can be attributed to a
significant number of HIV infections in children, breast milk has
been shown to potently inhibit HIV infectivity and to possess
several innate factors with in vitro anti-HIV inhibitory activity [4–
12]. Our results offer the first in vivo evidence that human breast
milk can strongly inhibit oral transmission of both cell-free and
cell-associated HIV.
The ability of human breast milk to inhibit cell-associated HIV
transmission in BLT mice is in contrast to in vitro studies suggesting
that milk does not inhibit cell-associated infection [54]. This
apparent discrepancy may be explained by the use of whole
human breast milk for our experiments. Specifically, the in vitro
experiments comparing breast milk inhibition of cell-free and cell-
associated HIV infection utilized the skim milk fraction of breast
Table 1. Oral transmission of T/F viruses in BLT mice.
HIV-1 Virus T/F Virus
Probable Route of
Transmission in Humans Oral Dose (TCIU) Oral Transmission Efficiency
JR-CSF N N/A 0.6610
6 75% (3 of 4)
1.4610
6 100% (10 of 10)
RHPA Y Vaginal 0.6610
6 66% (2 of 3)
CH044 Y Rectal 0.6610
6 100% (4 of 4)
CH077 Y Rectal 0.6610
6 33% (1 of 3)
Transmission is defined by the presence of RNA in the plasma of BLT mice.
doi:10.1371/journal.ppat.1002732.t001
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infection in the presence of whole breast milk or the skim milk
fraction will be needed to address this issue. However, since most
children at risk of HIV infection via breast milk do not receive
skim milk, the potential relevance of this in vitro observation may
be questionable. Nevertheless, inhibitory factors present in breast
milk may differ in their ability to inhibit cell-free versus cell-
associated HIV infection. While the skim milk fraction of human
breast milk possesses proteins with HIV inhibitory activity (i.e.
mucin, lactoferrin, bile salt-stimulated lipase and secretory
leukocyte protease inhibitor [SLPI]) [4–12], the lipid fraction
may contain additional factors that can inhibit transmission of cell-
free and/or cell-associated HIV. For example, increased concen-
trations of certain long-chain polyunsaturated fatty acids (LCPU-
FAs) in breast milk are associated with a decreased risk of HIV
breastfeeding transmission [55]. Although their ability to inhibit
cell-free versus cell-associated HIV infection has not been
experimentally tested to our knowledge, it has been hypothesized
that LCPUFAs may inhibit HIV infection by inactivating the
virus’ envelope, suppressing the release of HIV virions from the
host cell membrane and/or enhancing the viability of infected
CD4
+ T cells [56]. All together, our results highlight the protective
role of human breast milk against HIV transmission and suggest
that components in both the skim milk and lipid fractions may
contribute to its HIV inhibitory activity.
Despiteingestinglitersofbreastmilkoveraspanofseveralmonths
to years, the majority of infants bornto HIV-infected HAART naı ¨ve
women (,85%) do not acquire HIV during breastfeeding [14]. This
observation is in agreement with our data demonstrating the potent
invivoinhibitoryactivityofhumanbreastmilkonoraltransmissionof
both cell-free and cell-associated HIV following a single oral
exposure. Oral transmission of HIV in the presence of human
breast milk may require multiple exposures over time. Furthermore,
although increased levels of HIV in breast milk have been associated
with an increased risk for HIV transmission during breastfeeding,
several other maternal and infant factors have been associated with
breastfeeding transmission. Additional maternal factors include
seroconversion during lactation, CD4
+ T cells counts below 500
cells per mm
3, poor breast health (mastitis, nipple bleeding, etc), and
decreased levelsofalpha-defensinsin breastmilk.Infantsthatreceive
both breast milk and other food (mixed-feeding) are also more
susceptible to HIV transmission during breastfeeding as are infants
with oral thrush and decreased levels of salivary SLPI [reviewed in
[14]]. One remaining question is, therefore, whetherornot there are
differences in the babies or mothers or in the breast milk in the cases
where mother-to-child transmission does occur. In the future, it will
be important to compare the inhibitory activity of breast milk
obtained from HIV-infected mothers who transmit HIV to that of
HIV-infected mothers that do not transmit HIV in vivo. In addition,
in vivo experiments evaluating transmission in the presence of saliva
obtained from infants with low and high levels of salivary SLPI will
helpassessthecontributionoftheinhibitoryactivityofinfantsalivary
SLPI on oral transmission of cell-free and cell-associated HIV.
Collectively, our results demonstrate that BLT mice are an
attractive small animal model that can be utilized to study key
aspects of oral HIV transmission and to test the efficacy of HIV
vaccines, antiretroviral therapies and other preventative measures
aimed at reducing mother-to-child transmission of HIV during
breastfeeding. In addition, our data demonstrating the presence of
human immune cells in the oral cavity and GI tract of BLT mice
Figure 6. Oral transmission of cell-associated HIV in humanized
BLT mice. (A) BLT mice (n=7) were exposed orally to HIV-1JR-CSF
infected PBMCs. Transmission was monitored weekly by measuring the
plasma viral load and percentage of human CD4
+ T cells in peripheral
blood. A two-tailed Mann-Whitney U test was used to compare the
percentages of CD4
+ T cells in peripheral blood pre-exposure (week 0)
and post-exposure (p values,0.05 are indicated with an asterisk). (B)
Saliva and peripheral blood (PB) were harvested from five BLT mice
following oral HIV exposure with cell-associated HIV-1JR-CSF. Saliva and
peripheral blood were collected from BLT mice on the same day and
the corresponding saliva and peripheral blood viral loads for each
mouse are shown with the same color and shape. (C) HIV transmission
of cell associated virus administered via gavage into the stomach of BLT
mice. Shown is the viral load in the peripheral blood of BLT mice (n=4)
receiving a single dose of HIV-1JR-CSF infected PBMCs directly into the
stomach by gavage.
doi:10.1371/journal.ppat.1002732.g006
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pathogens that are transmitted orally and/or infect these tissues
(i.e. HCMV and EBV) and to answer fundamental questions about
human oral and gastrointestinal immunity.
Materials and Methods
Ethics statement
All animal experiments were conducted following NIH guide-
lines for housing and care of laboratory animals and in accordance
with The University of North Carolina at Chapel Hill (UNC-
Chapel Hill) regulations after review and approval by the UNC-
Chapel Hill Institutional Animal Care and Use Committee (permit
number 09-158).
Preparation of humanized BLT mice
Humanized BLT mice were prepared as previously described
[18–23]. Briefly, a 1–2 mm piece of human fetal liver tissue was
sandwiched between two pieces of autologous fetal thymus tissue
(Advanced Bioscience Resources, Alameda, CA) under the kidney
capsule of sublethally irradiated (300 cGy) 6–8 wk old NOD.Cg-
Prkdc
scid Il2rg
tm1Wjl/SzJ (NSG; The Jackson Laboratory, Bar
Harbor, ME) mice. Following implantation, mice were trans-
planted intravenously with hematopoietic CD34
+ stem cells
isolated from autologous human fetal liver tissue. Human immune
cell reconstitution was monitored in the peripheral blood of BLT
mice by flow cytometry every 3–4 weeks as previously described
[18–20,22,23]. Mice were maintained by the Division of
Laboratory Animal Medicine under specific-pathogen free condi-
tions at UNC-Chapel Hill.
Immunohistochemical analyses
Tissues for IHC were harvested from BLT mice and fixed in 4%
paraformaldehyde for 24 hr at 4uC, embedded in paraffin, cut into
5 mm sections and mounted onto poly-L-lysine coated glass slides.
Prior to paraffin embedding, the upper head region containing the
NALT was decalcified in a 0.24 M EDTA solution for 7–10 days
at 4uC. Following paraffin removal, antigen retrieval (DIVA
Figure 7. Oral Transmission of HIV in the presence of human breast milk. (A) In vitro inhibitory activity of human breast milk from five
different donors on infection with cell-free HIV. Infection was normalized to that of cells infected with virus in the absence of milk (positive control).
Note the strong inhibition observed for all 5 human breast milk samples tested. (B) Concentration dependence of the in vitro inhibitory activity of
human breast milk on infection with cell-free HIV. HIV infection was normalized to that of cells infected with virus in the absence of milk (positive
control) and compared to that of cells infected with virus in the presence of different amounts of whole human breast milk (at the indicated
dilutions). (C and D) Human breast milk potently inhibits cell-free and cell- associated HIV transmission in vivo. HIV transmission was examined by
exposing two groups of mice orally to cell-free (C) or cell-associated (D) HIV-1JR-CSF in the presence of breast milk or RPMI medium. The peripheral
blood viral load of mice was monitored weekly by real-time PCR. The mean peripheral blood viral load is shown for each exposure group. The limit of
detection for the assay is illustrated with a dashed line.
doi:10.1371/journal.ppat.1002732.g007
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specific Ig-binding sites (Background Sniper, Biocare Medical),
tissue sections were stained with primary antibodies overnight at
4uC and developed with a biotin-free HRP-polymer system
(MACH3 Mouse or Rabbit HRP-Polymer Detection, Biocare
Medical). All tissue sections were then counterstained with
hematoxylin. Images were taken with an upright Nikon Microphot
SA microscope with a DXM 1200 color camera and the white
balance and brightness adjusted in Adobe Photoshop CS4.
Primary antibodies directed against the following human
antigens were used to verify the presence of specific human
immune cell populations in the oral buccal mucosa (n=7),
submandibular salivary glands (n=5), CLN (n=4), NALT (n=4),
esophagus (n=7), stomach (n=5) and duodenum (n=4) of BLT
mice: CD3 (F7.2.38, Dako, Carpinteria, CA), CD4 (1F6, Leica,
Buffalo Grove, IL and SP35, GenWay, San Diego, CA), CD8
(C8/144B, Dako), CD11c (5D11, Leica), CD20 (L26, Biocare
Medical), CD45 LCA (2B11&PD7/26, Dako) and CD68 (KP1,
Dako). HIV-infected cells were detected with an antibody directed
against HIV p24 Gag (Kal-1, Dako). As a control, tissue sections
were stained with the following isotype control antibodies: mouse
IgG1k (Dako), mouse IgG2a (Dako) and rabbit Ig (Dako).
Exposure of humanized BLT mice to cell-free HIV-1
Stocks of HIV-1JR-CSF, HIV-1RHPA, HIV-1CH040, and HIV-
1CH077 [40–42,57] were prepared and titrated as previously
described [19–23]. Oral inoculations of mice were performed by
placing anesthetized BLT mice on their backs and instilling virus
Table 2. Description of BLT mice used to evaluate the effect of human breast milk on oral transmission of cell-free HIV-1.
At Time of Exposure At Time of Harvest






+ Post-Exposure (RNA copies/ml) SPL LN BM TO LIV LNG PB
None 1 56 83 2 154,486 ++ nd 2 nd nd +
2 49 87 3 7,637,214 nd nd nd nd nd nd nd
3 56 84 3 6,111,176 nd nd nd nd nd nd nd
4 66 85 3 5,856,373 nd nd nd nd nd nd nd
5 36 77 4 3,775,970 nd nd nd nd nd nd nd
6 44 82 6 2,063,909 + nd +++ 2 +
7 78 84 8 850,951 ++ + + +++
8 57 82 8 741,901 + nd +++ + +
9 32 69 6 827,983 + nd nd ++ + +
10 62 67 2 1,895,784 + nd +++ + nd
1a 11 72 84 3 Negative Re-exposed orally to HIV in medium (1b)
12 59 76 3 Negative Re-exposed orally to HIV in medium (1b)
13 44 86 3 Negative Re-exposed orally to HIV in medium (1b)
1b 11 76 84 1 Negative nd nd 2 nd nd nd 2
12 71 75 4 1,490,203 ++ + + +++
13 50 79 8 3,133,182 nd nd nd nd nd nd +
2 14 60 85 6 Negative 2 2 2 2 2 2 2
15 49 67 6 Negative 2 22 2 2 nd nd 2
16 64 72 6 Negative 2 2 2 2 nd nd 2
3 17 31 80 4 Negative 2 2 2 2 2 2 2
18 32 83 6 Negative 2 2 2 2 2 2 nd
19 40 82 3 Negative 2 2 2 2 2 2 2
20 47 82 6 Negative 2 2 2 2 2 2 2
4 21 56 79 3 Negative nd 2 2 2 2 2 nd
22 83 87 6 Negative 2 2 2 2 2 2 2
23 68 78 6 Negative 2 2 2 2 2 2 2
24 51 84 6 Negative 2 2 2 2 2 2 2
5 25 80 87 7 Negative 2 2 2 2 nd nd 2
26 55 85 6 Negative 2 2 2 2 2 2 2
27 53 89 7 Negative 2 2 2 2 nd nd 2
28 76 73 6 Negative 2 2 2 2 nd nd 2
*Real-time PCR results representative of DNA extracted from 5610
4–1.6610
6 cells or 15–50 ul blood. The assay limit of detection is 10 copies. SPL=spleen, LN=lymph
node, BM=bone marrow, TO=thymic organoid, LIV=liver, LNG=lung and PB=peripheral blood. The results are indicated as follows: (+) positive for HIV DNA, (2)
negative for HIV DNA, (nd) not determined.
doi:10.1371/journal.ppat.1002732.t002
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cavity were exposed to virus, initial oral exposure experiments
were performed with 2.82610
6 TCIU of HIV-1JR-CSF diluted in
RPMI medium or normal human breast milk (Innovative
Research, Novi, MI) to a final volume of 50 ml. Once all surfaces
of the oral cavity (palate, tongue, gums and epithelium lining the
cheek, lip and underside of the tongue) were exposed to virus, the
excess virus was pipetted out of the oral cavity and the volume
measured to determine the actual inoculum (approximately 0.9–
1.5610
6 TCIU of HIV-1JR-CSF). Mice were held in place for
5 minutes to ensure retention of the virus. Once mice recovered
from anesthesia, they were permitted immediate access to food
and water. Subsequent oral exposures to HIV-1JR-CSF were
performed using a total volume of 20 ml and 1.4610
6 TCIU of
virus. BLT mice exposed orally to HIV-1 T/F viruses were
administered 6610
5 TCIU of HIV-1RHPA, HIV-1CH040, HIV-
1CH077 or HIV-1JR-CSF (positive control) in 20 ml RPMI medium.
To assess the efficacy of systemic FTC/TDF PrEP on oral
transmission of cell free HIV in BLT mice, mice were
administered FTC/TDF (Gilead, Foster City, CA) intraperito-
nealy (3.5 mg and 5.2 mg, respectively) once daily for seven
consecutive days. Three hours after the third administration of
FTC/TDF, BLT mice were exposed orally to 1.4610
6 TCIU cell-
free HIV-1JR-CSF.
Table 3. Description of BLT mice used to evaluate the effect of human breast milk on oral transmission of cell-associated HIV-1.
At Time of Exposure At Time of Harvest







Exposure (RNA copies/ml) SPL LN BM TO LIV LNG PB
None 29 52 77 8 3,337,726 ++ + + +++
30 53 84 11 436,747 ++ + + +++
31 72 84 3 2,840,509 ++ + + +++
32 56 80 3 2,823,067 ++ + + +++
33 77 80 7 2,148,417 + nd +++ + +
34 78 82 7 1,924,391 + nd +++ + +
35 39 81 5 3,715,198 ++ + + +++
1 36 68 80 3 Negative 2 2 2 2 2 2 2
37 23 82 10 Negative 2 2 2 2 2 2 2
38 62 77 6 Negative 2 2 2 2 2 2 2
39 37 79 6 Negative 2 2 2 2 2 2 2
2 40 24 74 10 Negative 2 2 2 2 2 2 2
41 42 87 10 Negative 2 2 2 2 2 2 2
42 76 77 8 Negative 2 2 2 2 2 2 2
43 46 77 3 Negative 2 2 nd 2 2 2 nd
*Real-time PCR results representative of DNA extracted from 1610
5–1610
6 cells, snap frozen tissue or 15 ul blood. The assay limit of detection is 10 copies. SPL=spleen,
LN=lymph node, BM=bone marrow, TO=thymic organoid, LIV=liver, LNG=lung and PB=peripheral blood. The results are indicated as follows: (+) positive for HIV
DNA, (2) negative for HIV DNA, (nd) not determined.
doi:10.1371/journal.ppat.1002732.t003
Table 4. Oral transmission of cell-free HIV-1 in BLT mice following systemic FTC/TDF PrEP.
At Time of Exposure At Time of Harvest
Mouse PB Humanization Week
Number of







Exposure Plasma Viral Loads SPL LN BM TO LIV LNG PB
44 59 84 11 7 of 7 22 22 22 2
45 76 87 11 7 of 7 22 22 22 2
46 74 85 11 7 of 7 22 22 22 2
47 82 89 10 6 of 6 22 22 22 2
48 71 89 10 6 of 6 22 22 22 2
*Real-time PCR results representative of DNA extracted from 8.75610
5–1610
6 cells or 15 ul blood. The assay limit of detection is 10 copies. SPL=spleen, LN=lymph
node, BM=bone marrow, TO=thymic organoid, LIV=liver, LNG=lung and PB=peripheral blood. The results are indicated as follows: (+) positive for HIV DNA, (2)
negative for HIV DNA, (nd) not determined.
doi:10.1371/journal.ppat.1002732.t004
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gavage. Gavages were performed without anesthesia by threading
a feeding needle with a ball tip into the mouth and down the
esophagus of BLT mice until it reached the stomach. Next, using a
total volume of 100 ml, 1.4610
6 TCIU of HIV-1JR-CSF in RPMI
medium was directly introduced into the stomach.
Exposure of humanized BLT mice to cell-associated HIV-1
In order to generate cell-associated HIV, human PBMCs were
infected in vitro with HIV-1JR-CSF. PBMCs were cultured with
5 mg/ml PHA and 20 U/ml IL-2 in IMDM medium containing
10% FBS and 1% pen/strep for 3 days prior to infection. PBMCs
were then infected at a MOI of 0.1 with HIV-1JR-CSF by a 2 hr
spin infection (15006g for 2 hr at 25uC). Next, PBMCs were
washed three times with Dulbecco’s PBS and re-suspended in
IMDM medium containing 10% FBS and 1% pen/strep. Three to
four days post-infection, the percent of HIV-infected cells was
determined by intracellular staining for HIV p24 Gag (KC57-
FITC, Beckman Coulter, Brea, CA) using the Fix & Perm kit
(Invitrogen, Grand Island, NY). BLT mice were exposed orally to
3.75610
5 HIV p24 Gag
+ PBMCs (up to 1.9610
7 total PBMCs) in
RPMI medium or human breast milk using a total volume of 20 ml
as described for oral exposures of BLT mice to cell-free HIV.
Gavages were performed as described above with 3.75610
5 HIV
p24 Gag
+ HIV-1JR-CSF infected PBMCs (up to 1.6610
7 total
PBMCs) in RPMI medium using a total volume of 100 ml.
Analysis of HIV-1 infection in humanized BLT mice
Infection of humanized BLT mice with HIV was monitored in
peripheral blood plasma by measuring the levels of viral RNA with
a one-step reverse transcriptase real-time PCR assay using the
primers 59-CATGTTTTCAGCATTATCAGAAGGA-39 and 59-
TGCTTGATGTCCCCCCACT-39 and the MGB-probe 59-
FAM (6-carboxyfluorescein)-CCACCCCACAAGATTTAAA-
CACCATGCTAA-Q (6-carboxytetramehtylrhodamine)-39 [58];
assay sensitivity of 400 HIV RNA copies/ml [22]. The percentage
of human CD4
+ T cells in peripheral blood of BLT mice pre-
exposure (0–2 weeks prior to exposure) and post-exposure were
determined by flow cytometry. Saliva was collected following an
intraperitoneal injection with pilocarpine (100 ml at 1 mg/ml) to
stimulate saliva production and the levels of HIV RNA measured
using the real-time PCR assay described above. The presence of
viral DNA in tissues and peripheral blood collected from BLT
mice was determined by real-time PCR analysis of DNA extracted
from 5610
4–4610
6 cells or 15–50 ml peripheral blood cells as
previously described; assay sensitivity of 10 DNA copies
[19,20,22]. As a control, all samples were tested for the presence
of human gamma globulin DNA by real-time PCR.
In vitro assessment of the inhibitory activity of human
breast milk on cell-free HIV infection
Breast milk obtained from five HIV-negative women (Innova-
tive Research) at unknown time points during lactation was used to
test the in vitro inhibitory activity of human breast milk on cell-free
HIV infection. TZM-bl cells were plated in a white, opaque 96-
well plate the day prior to infection at 1610
5 cells per well.
Human breast milk or RPMI medium (5 ml) was incubated with
5 ml of HIV-1JR-CSF (6610
4 TCIU) for 10 min at RT. Since breast
milk was found to be toxic to TZM-bl cells, the breast milk-virus
mixture was diluted 1:400 with DMEM medium containing 10%
FBS, 25 mM HEPES, 1% pen/strep and 40 mg/ml DEAE
Dextran and then vortexed briefly before adding it to the TZM-
bl cells (3610
3 TCIU HIV-1JR-CSF per well). This dilution of milk
was found to be non-toxic to TZM-bl cells (data not shown).
48 hours post-infection, the medium was removed and 100 mlo f
One-Glo reagent (Promega, Madison, WI) supplemented with
Triton X-100 (final concentration of 0.01%) was added to
inactivate virus and to allow for the measurement of luciferase
activity. Luciferase was measured with a luminometer and the
results normalized to the luciferase activity of cells infected with
virus incubated with plain RPMI medium. For experiments
assessing the inhibitory activity of serial dilutions of whole breast
milk on HIV infection, breast milk was diluted with plain RPMI
medium prior to incubation with virus. All experiments were
performed in triplicate.
Statistical analyses
All statistical analyses were performed in Prism, version 5
(Graph pad, La Jolla, CA). We used a two-tailed Mann-Whitney U
test to compare the percentages of CD4
+ T cells in peripheral
blood pre- and post-exposure.
Supporting Information
Figure S1 Human reconstitution of the GE junction in
BLT mice. A portion of the stomach possessing the GE junction
was harvested from BLT mice for immunohistochemical analysis
to determine the presence of HIV target cells. The tissues
harvested were stained with the appropriate antibodies to verify
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